Akademik Veri Yönetim Sistemi
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.23, sa.2, ss.81-90, 2008 (ESCI, Scopus, TRDizin)
OBJECTIVES There is still no consensus on the eligibility criteria for breast conservation after neoadjuvant chemotherapy in patients with breast cancer. The present study investigated the long term outcome in patients with breast conservation following chemotherapy to determine its feasibility. METHODS Between January 1991 to July 2005, 29 patients with clinical stage 2 or 3 who underwent breast conservative surgery following chemotherapy, were included into the study. RESULTS The clinical stages before neoadjuvant chemotherapy were as follows: T-0 (n=1), T-1 (n=1), T-2 (n=14), T-3 (n=7), and T-4 (n=6); and N-0 (n=2), N-1 (n=9), and N-2 (n=17), and N-3 (n=1). Out of 4 ipsilateral breast tumor recurrences, 2 local recurrences (7%) were detected in the first 5 years, whereas 4 local recurrences (14%) were detected in the first 10 years. The 5-year and 10year local recurrence free rates were 91.5% and 75%, and the 5-year and 10-year overall survival rates were 92% and 78%, respectively. The 10-year local recurrence-free survival rate was only found to be higher in patients with T-0-(2) tumors compared to patients with T3-4 tumors (86%, vs 60%, p=0.078). CONCLUSION Breast conservation after neoadjuvant chemotherapy seems to be safe in selected patients with locally advanced disease including those with clinical T0-2 tumors before neoadjuvant chemotherapy.